Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 (ivosidenib) in previously-treated IDH1-mutant nonresectable or metastatic cholangiocarcinoma
2015-005117-72Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cholangiocarcinoma (CCA) comparing Ivosidenib with Placebo (2 arms). Primary endpoint: Progression-free survival (PFS). Started Mar 2017; status: completed.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2015-005117-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005117-72.